19615-4 |
N-desalkylflurazepam |
PrThr |
Urine |
Pt |
Ord |
Confirm |
|
ACTIVE |
N-desalkylflurazepam [Presence] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
19615-4 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Desalkylfluraz Ur Ql Cfm |
|
|
|
|
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Desalkyfluraz; Desalkylfluraz; Desalkylflurazepam; DRUG/TOXICOLOGY; Drugs; Flurazepam metabolite; GCMS; LC/MS/MS; norfludiazepam; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
19617-0 |
N-desalkylflurazepam |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
N-desalkylflurazepam [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19617-0 |
|
|
|
|
Both |
|
|
|
0 |
Desalkylfluraz Ur-mCnc |
|
|
|
Y |
|
Desalkyfluraz; Desalkylfluraz; Desalkylflurazepam; DRUG/TOXICOLOGY; Drugs; Flurazepam metabolite; Level; Mass concentration; norfludiazepam; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
19618-8 |
N-desalkylflurazepam cutoff |
MCnc |
Urine |
Pt |
Qn |
Screen |
|
ACTIVE |
N-desalkylflurazepam cutoff [Mass/volume] in Urine for Screen method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19618-8 |
|
Screen |
|
|
Observation |
|
|
|
0 |
Desalkylfluraz CtO Ur Scn-mCnc |
|
|
|
Y |
|
CtO; Desalkyfluraz; Desalkylfluraz; Desalkylflurazepam; DRUG/TOXICOLOGY; Drugs; Flurazepam metabolite; Level; Mass concentration; norfludiazepam; Point in time; QNT; Quan; Quant; Quantitative; Random; Scn; Scr; Scrn; UA; UR; Urn |
2.44 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
19619-6 |
N-desalkylflurazepam cutoff |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
N-desalkylflurazepam cutoff [Mass/volume] in Urine for Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19619-6 |
|
Confirm |
|
|
Observation |
|
|
|
0 |
Desalkylfluraz CtO Ur Cfm-mCnc |
|
|
|
Y |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CtO; Desalkyfluraz; Desalkylfluraz; Desalkylflurazepam; DRUG/TOXICOLOGY; Drugs; Flurazepam metabolite; GCMS; LC/MS/MS; Level; Mass concentration; norfludiazepam; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
1962-0 |
Bicarbonate |
SCnc |
Plas |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated Bicarbonate [Moles/volume] in Plasma |
|
DEL |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHEM |
|
1962-0 |
|
|
|
|
Both |
|
|
|
0 |
Deprecated HCO3 Plas-sCnc |
|
|
|
Y |
|
BIC; bicar; Bicarb; Chemistry; HCO3; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration |
2.7 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
19620-4 |
Nitrazepam |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
Nitrazepam [Presence] in Urine by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
19620-4 |
|
Screen |
|
|
Both |
|
|
|
0 |
Nitrazepam Ur Ql Scn |
|
|
|
|
|
Alodorm; APODORM; AREM; Dormigen; Dormo-puren; DRUG/TOXICOLOGY; Drugs; Eatan N; Imeson; Insoma; Ipersed; Mitidin; Mogadan; Mogadon; Nitrados; Nitrazepan; Novanox; Ordinal; Ormodon; Paxadorm; Pelson; Point in time; PR; QL; Qual; Qualitative; Random; Remnos; Scn; Scr; Screen; Scrn; Serenade; Somnibel n; Somniper; Somnite; Surem; UA; UR; Urn |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
19621-2 |
Nitrazepam |
PrThr |
Urine |
Pt |
Ord |
Confirm |
|
ACTIVE |
Nitrazepam [Presence] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
19621-2 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Nitrazepam Ur Ql Cfm |
|
|
|
|
|
Alodorm; APODORM; AREM; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Dormigen; Dormo-puren; DRUG/TOXICOLOGY; Drugs; Eatan N; GCMS; Imeson; Insoma; Ipersed; LC/MS/MS; Mitidin; Mogadan; Mogadon; Nitrados; Nitrazepan; Novanox; Ordinal; Ormodon; Paxadorm; Pelson; Point in time; PR; QL; Qual; Qualitative; Random; Remnos; Screen; Serenade; Somnibel n; Somniper; Somnite; Surem; UA; UR; Urn |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
19622-0 |
Nitrazepam cutoff |
MCnc |
Urine |
Pt |
Qn |
Screen |
|
ACTIVE |
Nitrazepam cutoff [Mass/volume] in Urine for Screen method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19622-0 |
|
Screen |
|
|
Observation |
|
|
|
0 |
Nitrazepam CtO Ur Scn-mCnc |
|
|
|
Y |
|
Alodorm; APODORM; AREM; CtO; Dormigen; Dormo-puren; DRUG/TOXICOLOGY; Drugs; Eatan N; Imeson; Insoma; Ipersed; Level; Mass concentration; Mitidin; Mogadan; Mogadon; Nitrados; Nitrazepan; Novanox; Ormodon; Paxadorm; Pelson; Point in time; QNT; Quan; Quant; Quantitative; Random; Remnos; Scn; Scr; Scrn; Serenade; Somnibel n; Somniper; Somnite; Surem; UA; UR; Urn |
2.44 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
19623-8 |
Nitrazepam cutoff |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Nitrazepam cutoff [Mass/volume] in Urine for Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19623-8 |
|
Confirm |
|
|
Observation |
|
|
|
0 |
Nitrazepam CtO Ur Cfm-mCnc |
|
|
|
Y |
|
Alodorm; APODORM; AREM; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CtO; Dormigen; Dormo-puren; DRUG/TOXICOLOGY; Drugs; Eatan N; GCMS; Imeson; Insoma; Ipersed; LC/MS/MS; Level; Mass concentration; Mitidin; Mogadan; Mogadon; Nitrados; Nitrazepan; Novanox; Ormodon; Paxadorm; Pelson; Point in time; QNT; Quan; Quant; Quantitative; Random; Remnos; Serenade; Somnibel n; Somniper; Somnite; Surem; UA; UR; Urn |
2.44 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
19624-6 |
Nordiazepam |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
Nordiazepam [Presence] in Urine by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
19624-6 |
|
Screen |
|
|
Both |
|
|
|
0 |
Nordiazepam Ur Ql Scn |
|
|
|
|
|
Calmday; Chlordiazepoxide metabolite; Desmethyldiazepam; Diazepam metabolite; Dimethyldiazepam; DRUG/TOXICOLOGY; Drugs; Madar; n-dimethyldiazepam; Nordaz; Nordazepam; Nordiaze; Ordinal; Point in time; PR; Praxadium; Prazepam metabolite; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; Stilny; Tranxilium N; UA; UR; Urn; Vegesan |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
19626-1 |
Nordiazepam cutoff |
MCnc |
Urine |
Pt |
Qn |
Screen |
|
ACTIVE |
Nordiazepam cutoff [Mass/volume] in Urine for Screen method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19626-1 |
|
Screen |
|
|
Observation |
|
|
|
0 |
Nordiazepam CtO Ur Scn-mCnc |
|
|
|
Y |
|
Calmday; Chlordiazepoxide metabolite; CtO; Desmethyldiazepam; Diazepam metabolite; Dimethyldiazepam; DRUG/TOXICOLOGY; Drugs; Level; Madar; Mass concentration; n-dimethyldiazepam; Nordaz; Nordazepam; Nordiaze; Point in time; Praxadium; Prazepam metabolite; QNT; Quan; Quant; Quantitative; Random; Scn; Scr; Scrn; Stilny; Tranxilium N; UA; UR; Urn; Vegesan |
2.44 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
19627-9 |
Nordiazepam cutoff |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Nordiazepam cutoff [Mass/volume] in Urine for Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19627-9 |
|
Confirm |
|
|
Observation |
|
|
|
0 |
Nordiazepam CtO Ur Cfm-mCnc |
|
|
|
Y |
|
Calmday; Cfm; Chlordiazepoxide metabolite; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CtO; Desmethyldiazepam; Diazepam metabolite; Dimethyldiazepam; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Madar; Mass concentration; n-dimethyldiazepam; Nordaz; Nordazepam; Nordiaze; Point in time; Praxadium; Prazepam metabolite; QNT; Quan; Quant; Quantitative; Random; Stilny; Tranxilium N; UA; UR; Urn; Vegesan |
2.73 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
19628-7 |
Norfluoxetine |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
Norfluoxetine [Presence] in Urine by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
19628-7 |
|
Screen |
|
|
Both |
|
|
|
0 |
Norfluoxetine Ur Ql Scn |
|
|
|
|
|
(S)-Norfluoxetine; Desmethylfluoxetine; DRUG/TOXICOLOGY; Drugs; Fluoxetine metabolite; Norfluoxetin; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; Seproxetine; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
19629-5 |
Norfluoxetine |
PrThr |
Urine |
Pt |
Ord |
Confirm |
|
ACTIVE |
Norfluoxetine [Presence] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
19629-5 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Norfluoxetine Ur Ql Cfm |
|
|
|
|
|
(S)-Norfluoxetine; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Desmethylfluoxetine; DRUG/TOXICOLOGY; Drugs; Fluoxetine metabolite; GCMS; LC/MS/MS; Norfluoxetin; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Seproxetine; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
1963-8 |
Bicarbonate |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Bicarbonate [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHEM |
|
1963-8 |
|
|
|
|
Both |
|
|
|
0 |
HCO3 SerPl-sCnc |
|
|
|
Y |
|
BIC; bicar; Bicarb; Chemistry; HCO3; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SBC; SBIC; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.73 |
1 |
|
|
|
|
|
|
|
mmol/L |
|
|
Changed from Ser to Ser/Plas since there is no clinical difference in bicarbonate levels in serum or plasma. |
0 |
19630-3 |
Norfluoxetine cutoff |
MCnc |
Urine |
Pt |
Qn |
Screen |
|
ACTIVE |
Norfluoxetine cutoff [Mass/volume] in Urine for Screen method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19630-3 |
|
Screen |
|
|
Observation |
|
|
|
0 |
Norfluoxetine CtO Ur Scn-mCnc |
|
|
|
Y |
|
(S)-Norfluoxetine; CtO; Desmethylfluoxetine; DRUG/TOXICOLOGY; Drugs; Fluoxetine metabolite; Level; Mass concentration; Norfluoxetin; Point in time; QNT; Quan; Quant; Quantitative; Random; Scn; Scr; Scrn; Seproxetine; UA; UR; Urn |
2.42 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
19631-1 |
Norfluoxetine cutoff |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Norfluoxetine cutoff [Mass/volume] in Urine for Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19631-1 |
|
Confirm |
|
|
Observation |
|
|
|
0 |
Norfluoxetine CtO Ur Cfm-mCnc |
|
|
|
Y |
|
(S)-Norfluoxetine; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CtO; Desmethylfluoxetine; DRUG/TOXICOLOGY; Drugs; Fluoxetine metabolite; GCMS; LC/MS/MS; Level; Mass concentration; Norfluoxetin; Point in time; QNT; Quan; Quant; Quantitative; Random; Seproxetine; UA; UR; Urn |
2.42 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
19632-9 |
Norpropoxyphene |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
Norpropoxyphene [Presence] in Urine by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
19632-9 |
|
Screen |
|
|
Both |
|
|
|
0 |
Norpropoxyph Ur Ql Scn |
|
|
|
|
|
DRUG/TOXICOLOGY; Drugs; n-desmethylproproxyphene; Norpropoxyp; Ordinal; Point in time; PR; Propoxyphene metabolite; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; UA; UR; Urn |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
19635-2 |
Norpropoxyphene |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Norpropoxyphene [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19635-2 |
|
|
|
|
Both |
|
|
|
0 |
Norpropoxyph Ur-mCnc |
|
|
|
Y |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; n-desmethylproproxyphene; Norpropoxyp; Point in time; Propoxyphene metabolite; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
19636-0 |
Norpropoxyphene cutoff |
MCnc |
Urine |
Pt |
Qn |
Screen |
|
ACTIVE |
Norpropoxyphene cutoff [Mass/volume] in Urine for Screen method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19636-0 |
|
Screen |
|
|
Observation |
|
|
|
0 |
Norpropoxyph CtO Ur Scn-mCnc |
|
|
|
Y |
|
CtO; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; n-desmethylproproxyphene; Norpropoxyp; Point in time; Propoxyphene metabolite; QNT; Quan; Quant; Quantitative; Random; Scn; Scr; Scrn; UA; UR; Urn |
2.44 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
19637-8 |
Norpropoxyphene cutoff |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Norpropoxyphene cutoff [Mass/volume] in Urine for Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19637-8 |
|
Confirm |
|
|
Observation |
|
|
|
0 |
Norpropoxyph CtO Ur Cfm-mCnc |
|
|
|
Y |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CtO; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; n-desmethylproproxyphene; Norpropoxyp; Point in time; Propoxyphene metabolite; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.44 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
19638-6 |
Oxazepam |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
Oxazepam [Presence] in Urine by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
19638-6 |
|
Screen |
|
|
Both |
|
|
|
0 |
Oxazepam Ur Ql Scn |
|
|
|
|
|
Alepam; Chlordiazepoxide metabolite; Diazepam metabolite; DRUG/TOXICOLOGY; Drugs; Ordinal; Point in time; PR; Prazepam metabolite; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; Serax; Temazepam metabolite; UA; UR; Urn |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
19639-4 |
Oxazepam |
PrThr |
Urine |
Pt |
Ord |
Confirm |
|
ACTIVE |
Oxazepam [Presence] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
19639-4 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Oxazepam Ur Ql Cfm |
|
|
|
|
|
Alepam; Cfm; Chlordiazepoxide metabolite; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Diazepam metabolite; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Ordinal; Point in time; PR; Prazepam metabolite; QL; Qual; Qualitative; Random; Screen; Serax; Temazepam metabolite; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
1964-6 |
Bicarbonate |
SCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Bicarbonate [Moles/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHEM |
|
1964-6 |
|
|
|
|
Both |
|
|
|
0 |
HCO3 Ur-sCnc |
|
|
|
Y |
|
BIC; bicar; Bicarb; Chemistry; HCO3; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration; UA; UR; Urn |
2.73 |
1 |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
19640-2 |
Oxazepam cutoff |
MCnc |
Urine |
Pt |
Qn |
Screen |
|
ACTIVE |
Oxazepam cutoff [Mass/volume] in Urine for Screen method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
19640-2 |
|
Screen |
|
|
Observation |
|
|
|
0 |
Oxazepam CtO Ur Scn-mCnc |
|
|
|
Y |
|
Alepam; Chlordiazepoxide metabolite; CtO; Diazepam metabolite; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; Prazepam metabolite; QNT; Quan; Quant; Quantitative; Random; Scn; Scr; Scrn; Serax; Temazepam metabolite; UA; UR; Urn |
2.44 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |